HALOZYME THERAPEUTICS Reports $493 million in Latest Quarterly Results
HALOZYME THERAPEUTICS reported quarterly results highlighted by Revenue Increased 39% YOY to $493 million, according to its earnings release filed with an 8-K Thursday.
Revenue Increased 44% YOY to $341 million. Total Revenue Increased 39% YOY to $493 million. Royalty Revenue Increased 44% YOY to $341 million.
Results detail
Further figures in the release included Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%; Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118% 1; Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45%.
The filing is an Item 2.02 results announcement furnished with Exhibit 99.1. Comparisons use the year-earlier period as presented by HALOZYME THERAPEUTICS unless the release specifies another baseline. Where both GAAP and non-GAAP metrics appear, both are summarized when the extract includes them.
Segment mix, cash flow and any outlook language in the release are the usual secondary reads after the headline revenue and earnings figures.
Why it matters
For retail investors, the HALOZYME THERAPEUTICS print is a check on whether growth, margins and cash generation are moving together. The figures above come from the company’s Exhibit 99.1 earnings materials; how they stack up against the prior-year run rate and any guide published with the release will shape the near-term debate.
By the numbers
- Revenue Increased 39% YOY to $493 million
- Revenue Increased 44% YOY to $341 million
- Total Revenue Increased 39% YOY to $493 million
- Royalty Revenue Increased 44% YOY to $341 million
- Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38%
- Non-GAAP Diluted EPS of $8.75 - $9.05, YOY Growth of 111% - 118% 1
Sources
- HALOZYME THERAPEUTICS, INC. Form 8-K with quarterly financial results, filed Nov. 5, 2026 (accession 0001159036-26-000143)
This article is for informational and educational purposes only and is not investment advice. It is not a recommendation to buy or sell any security.
Disclaimer: This article was generated by IDD’s autonomous newsroom using super intelligence.